Jones Trading Rates ProQR Therapeutics (PRQR) buy

Jones Trading maintains a buy rating for ProQR Therapeutics with a $10 price target, a 446.45% upside from the current price.

By EarningsIQ Research Desk · Published Jun 27, 2026, 3:03 AM EDT · Updated Jul 1, 2026, 5:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Jones Trading rated ProQR Therapeutics N.V. ($PRQR) "buy" with a $10 price target on June 26, 2026.

Since the rating, $PRQR is up 12.4% after 1 week, up 13.1% after 1 month and down 14.4% to date (from the $1.53 close on Jun 26, 2026).

PRQR ProQR Therapeutics N.V.

$1.31 -34.17% year to date

Daily close · Oct 16, 2026

Key Points

Jones Trading reiterated its buy rating on ProQR Therapeutics with a $10 price target on June 26, 2026.
Jones Trading's $10 price target implies 446.45% upside from ProQR Therapeutics N.V.'s ($PRQR) current $1.83 share price.
ProQR Therapeutics, trading at $1.56, has a market cap of $161.2 million and a 52-week range of $1.33 to $3.10.
Insider Hinsch Gylvin Lykke bought 14,495 shares on June 2, 2026, while major funds like Aberdeen Group increased their stakes.

Get $PRQR trade alerts by text

We text you when insiders, Congress or big funds trade $PRQR. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated ProQR Therapeutics N.V. alert may contain errors. Disclosures

Jones Trading reiterated its buy rating on ProQR Therapeutics N.V. (NasdaqCM: PRQR) on June 26, 2026. Analyst Catherine Novack set a price target of $10, suggesting significant upside from the current trading price of $1.56.

Analyst rating track record

Jones Trading vs. the S&P 500

YTD return +60.37% hypothetical

All-time return +168.06% S&P 500 +28.98%

vs. S&P 500 +139.08% ahead of the index

Hypothetical returns from Jones Trading's disclosed trades, not real profit or advice. How we model this.

Other Institutional Activity in ProQR Therapeutics

Several institutional investors also showed interest in ProQR Therapeutics. Aberdeen Group PLC increased its holdings by 366,289 shares, resulting in a total of 3,316,965 shares valued at approximately $5.37 million, marking a 12.4% increase. Privium Fund Management B.V. added 109,387 shares, bringing its total to 5,467,149 shares worth about $8.86 million, a 2.0% increase. Meanwhile, SIO Capital Management, LLC reduced its stake by 209,466 shares, ending with 1,954,715 shares valued at around $3.17 million, representing a 9.7% decrease.

ProQR Therapeutics N.V. Stock Holds Steady

Shares of ProQR Therapeutics traded at $1.56 on Saturday. The company has a market cap of $161.2 million and a beta of 0.061, indicating low volatility. The stock's 52-week range spans from $1.33 to $3.10, with a 50-day moving average of $1.60 and a 200-day moving average of $1.90. ProQR's financial health is supported by a current ratio of 2.48 and a quick ratio of 2.39, though it carries a debt-to-equity ratio of 41.85.

12-month forecast

$PRQR price target

ProQR Therapeutics N.V. daily closes and this analyst's $10 target. Not advice.

Recent Earnings

ProQR Therapeutics reported revenue of $13.64 million, though it saw a decline with a revenue growth rate of -57.1%. The company is not profitable, with a net margin of 0.0% and a return on equity of -78.1%. The next earnings report is expected on August 6, 2026.

Insider Buying and Selling at ProQR Therapeutics N.V.

On June 2, 2026, an insider named Hinsch Gylvin Lykke purchased 14,495 shares of ProQR Therapeutics. This transaction was not part of a pre-planned trading program.

Analysts Set New Price Targets

On June 26, 2026, Chardan Capital also maintained its buy rating with a price target of $3.00. The consensus among analysts is a buy rating, with a mean target price of $8.88 based on eight opinions.

About ProQR Therapeutics

ProQR Therapeutics N.V. is a biotechnology company based in Leiden, Netherlands. It focuses on developing RNA editing technology through its Axiomer platform to treat genetic disorders. The company's leading products target various health conditions, including cholestatic diseases and Rett syndrome. Under the leadership of CEO Daniel Anton de Boer, ProQR collaborates with Eli Lilly to advance treatments for genetic disorders in the liver and nervous system.

Bottom Line

Jones Trading's reiteration of a buy rating for ProQR Therapeutics reflects optimism in the company's potential, despite its current low price. Investors keep a close watch on such analyst ratings, though it's important to remember that these insights are based on past performance and market conditions. ProQR's recent insider activity and institutional interest suggest that stakeholders are paying attention to its future prospects.